These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 28949250)

  • 21. Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting.
    Wick JA; Schmidlen T; Grande K; Moretz C; Ashcraft K; Green J; Moyer N; Blaxall BC
    J Am Pharm Assoc (2003); 2023; 63(1):188-192. PubMed ID: 36243653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARC report: a perspective on the state of clinical pharmacogenomics testing.
    Eichmeyer J; Rogers S; Formea CM; Giri J; Jones JS; Schnettler E; Schmidlen T; Glogowski E; Kurz RN
    Pharmacogenomics; 2020 Jul; 21(11):809-820. PubMed ID: 32635876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
    Dias MM; Sorich MJ; Rowland A; Wiese MD; McKinnon RA
    Pharm Res; 2017 Aug; 34(8):1544-1550. PubMed ID: 28236061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing.
    Drozda K; Pacanowski MA
    Pharmacotherapy; 2017 Sep; 37(9):1000-1004. PubMed ID: 28605049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    Verbelen M; Weale ME; Lewis CM
    Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
    Hess GP; Fonseca E; Scott R; Fagerness J
    Genet Res (Camb); 2015 Jun; 97():e13. PubMed ID: 26030725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
    van der Wouden CH; Böhringer S; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VHM; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Rial-Sebbag E; Samwald M; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; van Zwet E; Swen JJ; Guchelaar HJ;
    Pharmacogenet Genomics; 2020 Aug; 30(6):131-144. PubMed ID: 32317559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.
    Haidar CE; Crews KR; Hoffman JM; Relling MV; Caudle KE
    Annu Rev Genomics Hum Genet; 2022 Aug; 23():449-473. PubMed ID: 35537468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomics: Prescribing Precisely.
    Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
    Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities.
    Chenoweth MJ; Giacomini KM; Pirmohamed M; Hill SL; van Schaik RHN; Schwab M; Shuldiner AR; Relling MV; Tyndale RF
    Clin Pharmacol Ther; 2020 Jan; 107(1):57-61. PubMed ID: 31696505
    [No Abstract]   [Full Text] [Related]  

  • 31. Individualizing pharmacogenomic test results in the context of the microbiome.
    Haga SB
    Per Med; 2020 Nov; 17(6):459-468. PubMed ID: 33026284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
    Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
    Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study.
    Riddle D; Gregoski M; Baker K; Dumas B; Jenkins CH
    Pharmacogenomics; 2016 Apr; 17(6):593-602. PubMed ID: 27023204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?
    Hughes DA
    Clin Pharmacol Ther; 2018 May; 103(5):749-751. PubMed ID: 29435984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
    Liko I; Lee YM; Stutzman DL; Blackmer AB; Deininger KM; Reynolds AM; Aquilante CL
    Pharmacogenomics; 2021 Apr; 22(5):263-274. PubMed ID: 33657875
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation.
    Scott SA; Swen JJ
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33801919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation.
    Deininger KM; Tran JN; Tsunoda SM; Young GK; Lee YM; Anderson HD; Page Ii RL; Hirsch JD; Aquilante CL
    Pharmacogenomics; 2019 Dec; 20(18):1291-1302. PubMed ID: 31755847
    [No Abstract]   [Full Text] [Related]  

  • 39. Implementation of wide-scale pharmacogenetic testing in primary care.
    Natasha Petry ; Baye J; Aifaoui A; Wilke RA; Lupu RA; Savageau J; Gapp B; Massmann A; Hahn D; Hajek C; Schultz A
    Pharmacogenomics; 2019 Aug; 20(12):903-913. PubMed ID: 31453774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.